Cytoreason

Cytoreason company information, Employees & Contact Information

Explore related pages

Related company profiles:

CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models. With its extensive database of public and proprietary data, the company maps human diseases – tissue by tissue and cell by cell. Researchers of all levels rely on CytoReason’s technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain valuable tools to manage and optimize entire drug portfolios.

Company Details

Employees
129
Founded
-
Address
16th Floor, Circular Building Azrieli Center,israel
Email
ze****@****son.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Tel Aviv
Looking for a particular Cytoreason employee's phone or email?

Cytoreason Questions

News

Israeli startup CytoReason raises $80M to expand AI model, open hub in Massachusetts - Mobi Health News

Israeli startup CytoReason raises $80M to expand AI model, open hub in Massachusetts Mobi Health News

CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal - GlobeNewswire

CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal GlobeNewswire

CytoReason and Summit Pharmaceuticals International Announce the Introduction of an AI Platform to One of Japan's Top Pharmaceutical Companies - PR Newswire

CytoReason and Summit Pharmaceuticals International Announce the Introduction of an AI Platform to One of Japan's Top Pharmaceutical Companies PR Newswire

CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts - Business Wire

CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts Business Wire

Israel’s CytoReason, S. Korea’s Helixrus partner on machine learning for drug development - www.israelhayom.com

Israel’s CytoReason, S. Korea’s Helixrus partner on machine learning for drug development www.israelhayom.com

AI disease modelling startup CytoReason to scale up in US - Unpacked

AI disease modelling startup CytoReason to scale up in US Unpacked

CytoReason Shoots For $110M Net With Pfizer Partnership - Crunchbase News

CytoReason Shoots For $110M Net With Pfizer Partnership Crunchbase News

Nvidia, Pfizer lead $80 mln funding for Israeli medical AI tech firm CytoReason - Reuters

Nvidia, Pfizer lead $80 mln funding for Israeli medical AI tech firm CytoReason Reuters

CytoReason raises $80 million, including from NVIDIA and Pfizer, to scale its AI disease models - CTech

CytoReason raises $80 million, including from NVIDIA and Pfizer, to scale its AI disease models CTech

CytoReason secures $80m investment for AI expansion - Pharmaceutical Technology

CytoReason secures $80m investment for AI expansion Pharmaceutical Technology

CytoReason, Pfizer ink $110M, 5-year extension of AI-powered drug development deal - Fierce Biotech

CytoReason, Pfizer ink $110M, 5-year extension of AI-powered drug development deal Fierce Biotech

CytoReason’s AI Earns Pfizer Extension Deal - Medical Device and Diagnostic industry

CytoReason’s AI Earns Pfizer Extension Deal Medical Device and Diagnostic industry

Pfizer and AI firm CytoReason extend alliance - drugdiscoverytrends.com

Pfizer and AI firm CytoReason extend alliance drugdiscoverytrends.com

CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms - BioSpace

CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms BioSpace

Israel’s CytoReason Launches AI Drug Discovery Platform In Japanese Market - NoCamels

Israel’s CytoReason Launches AI Drug Discovery Platform In Japanese Market NoCamels

Pfizer extends cooperation deal with Israeli AI drug development firm CytoReason - The Times of Israel

Pfizer extends cooperation deal with Israeli AI drug development firm CytoReason The Times of Israel

CytoReason raises $20 million from Pfizer for AI drug discovery and development platform - CTech

CytoReason raises $20 million from Pfizer for AI drug discovery and development platform CTech

Japanese pharmaceutical firm taps Israel’s CytoReason for AI drug development - The Times of Israel

Japanese pharmaceutical firm taps Israel’s CytoReason for AI drug development The Times of Israel

CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology - PR Newswire

CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology PR Newswire

Sanofi Extends Deal with CytoReason to License IBD Disease Modeling - Genetic Engineering and Biotechnology News

Sanofi Extends Deal with CytoReason to License IBD Disease Modeling Genetic Engineering and Biotechnology News

Pfizer backs Israel’s CytoReason, inks new research deal for AI drug development - The Times of Israel

Pfizer backs Israel’s CytoReason, inks new research deal for AI drug development The Times of Israel

Sanofi and CytoReason Target IBD in Expanded Collaboration (Updated) - BioSpace

Sanofi and CytoReason Target IBD in Expanded Collaboration (Updated) BioSpace

Israeli start-up secured a deal with Pfizer just a year after launch - Jewish News

Israeli start-up secured a deal with Pfizer just a year after launch Jewish News

Swiss pharma firm Ferring, Israel’s CytoReason join to battle bowel disease - The Times of Israel

Swiss pharma firm Ferring, Israel’s CytoReason join to battle bowel disease The Times of Israel

Sanofi extends cooperation with Israel’s CytoReason for bowel disease drug discovery - The Times of Israel

Sanofi extends cooperation with Israel’s CytoReason for bowel disease drug discovery The Times of Israel

Israeli AI disease models co CytoReason raises $80m - Globes - Israel Business News

Israeli AI disease models co CytoReason raises $80m Globes - Israel Business News

Poolbeg Pharma PLC Announces Influenza AI model build completed - ACCESS Newswire

Poolbeg Pharma PLC Announces Influenza AI model build completed ACCESS Newswire

Top Cytoreason Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant